Condition: Cervical Cancer TNM Staging Regional Lymph Nodes (N) · Sponsor: University Hospital, Toulouse
The main objective of this study is to determine whether neoadjuvant chemotherapy with Carboplatin and paclitaxel plus standard cisplatin-based chemoradiation with extended fields improves overall survival rates compared to standard therapy alone in women with cervical cancer with paraaortic lymph node involvement. Women in the experimental arm will receive neoadjuvant chemotherapy with carboplatin and paclitaxel every 21 days during 3 cycles followed by standard therapy with extended field external radiation therapy and concomitant chemotherapy. Women in the control arm will receive standard therapy with extended field external radiation therapy and concomitant chemotherapy. 310 patients will be recruited during 4.5 years, with 3 years of follow up period.
This description comes directly from the study's public registry record.
Stéphanie MOTTON, MD · +335 61 32 37 08 · motton.stephanie@iuct-oncopole.fr
Mariavah RODRIGUEZ, CRA · +335 31 15 64 51 · rodriguez.mariavah@chu-toulouse.fr
Always discuss trial participation with your own doctor first.
| CHU de Bordeaux | Bordeaux, France | Recruiting |
| Centre Jean Perrin | Clermont-Ferrand, France | Recruiting |
| CHI Créteil | Créteil, France | Recruiting |
| Institut Paoli Calmettes | Marseille, France | Recruiting |
| CH Lyon Sud | Pierre-Bénite, France | Recruiting |
| CHU de Poitiers | Poitiers, France | Recruiting |
| Institut de Cancérologie de l'Ouest - Nantes | Saint-Herblain, France | Recruiting |
| CHU La Réunion | Saint-Pierre, France | Recruiting |
| Clinique Pasteur | Toulouse, France | Recruiting |
| University Hospital Toulouse | Toulouse, France | Recruiting |
| CHU de Tours | Tours, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03534713